IP Library Granted Patent US 8,476,043
Granted Patent B2
US 8,476,043 · App. 12/631,577 · Granted Jul 2, 2013

Inhibitors for the soluble epoxide hydrolase

Inventors: Bruce D. Hammock (Davis, CA); In-Hae Kim (Davis, CA); Christophe Morisseau (West Sacramento, CA); Takaho Watanabe (Kanagawa-ken, JP); John W. Newman (Davis, CA)
Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,476,043
App. No.
12/631,577
Granted
Jul 2, 2013
Kind
B2
Abstract

Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

Claims (21)

1. A compound having a formula:

and its pharmaceutically acceptable salts, wherein

R 1 is selected from the group consisting of cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, adamantyl, noradamantyl, and phenyl, wherein the phenyl group is either unsubstituted or substituted with from one to three substituents selected from the group consisting of halogen, lower alkyl, lower halo alkyl, lower alkoxy, lower haloalkoxy, C 3 -C 5 cycloalkyl and cyano;

P 1 is —NHC(O)NH—;

P 2 is selected from the group consisting of —C(O)—, —O(CH 2 CH 2 O) q —, and —C(O)O—;

P 3 is —C(O)OR 2 , wherein R 2 is a member selected from the group consisting of hydrogen, methyl and ethyl;

the subscripts n and m are each 1, and the subscript q is 0 to 6;

L 1 is cyclohexylene; and

L 2 is a phenylene.

2. The compound in accordance with claim 1 , wherein R 1 is phenyl substituted with from 1 to 3 substituents selected from the group consisting of halogen, methyl, isopropyl, methoxy, trifluoromethyl, and trifluoromethoxy.

3. The compound in accordance with claim 2 , wherein R 1 is 4-substituted phenyl.

4. The compound in accordance with claim 3 , wherein the R 1 is 4-trifluoromethoxyphenyl.

5. The compound in accordance with claim 1 , wherein P 2 is —O(CH 2 CH 2 O) q —; and wherein q is 0.

6. The compound in accordance with claim 1 , wherein L 1 is trans-substituted.

7. The compound in accordance with claim 1 , wherein L 2 is a 1,2-, 1,3-, or 1,4-linked phenylene.

8. The compound in accordance with claim 7 , wherein L 2 is a 1,3- or 1,4-linked phenylene.

9. The compound in accordance with claim 1 ,

R 1 is 4-trifluoromethoxyphenyl;

P 2 is —O—;

L 1 is 1,3- or 1,4-cyclohexylene; and

L 2 is a 1,3- or 1,4-linked phenylene.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 25, 2011
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026640/0996 →
CONFIRMATORY LICENSE Recorded Feb 16, 2010
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023938/0496 →
Continuity (3)
Continuation 11256685 · Oct 20, 2005
Provisional Application 60651487 · Oct 20, 2004
Related Publication 20110021448A1 · Jan 27, 2011